Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemtuzumab Ozogamicin vs ATRA Maintenance in APL
NCT00962767Phase 3Completed
- Sponsor
- Pfizer
- Start
- May 2002
- Primary completion
- Dec 2007
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
01
Overview
A Phase 3 trial of gemtuzumab ozogamicin in acute promyelocytic leukemia (APL), sponsored by Pfizer. Started May 2002; status: completed.
02
Drugs
gemtuzumab ozogamicin
03
Conditions
acute promyelocytic leukemia (APL)
Beyond the preview
Go deeper on NCT00962767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00962767.